LGM Pharma announced the approval of its ANDA for a leading antihistamine, marking a significant milestone that positions the company to capitalize on the commingling of volume and off-patent sales. The launch is expected to bolster LGM Pharma’s generic revenue streams and solidify its presence in the lucrative, entry-level antihistamine market.